Business
Grant of share options to the CEO
Grant of share options to the CEO.
About this update from Shield Therapeutics Plc
[{"type":"text","content":"\n\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\n \nGrant of share options to the Chief Executive Officer\n \nLondon, UK, 06 June 2023: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/ Feraccru® (ferric maltol), announces that on 02 June 2023 it granted share awards in the form of options over ordinary shares in the capital of the Company (\"Ordinary Shares\") under Shield Therapeutics' Retention and Performance Share Plan (\"RPSP\"). \n \nIn accordance with the requirements of the EU Market Abuse Regulations the following options have been granted to Greg Madison who is deemed a PDMR:\n \n\n\n\nName\n\n\nOption Plan\n\n\nNumber of Ordinary Shares under Option\n\n\nVesting Date\n\n\n\n\nGreg Madison\n\n\nRPSP\n\n\n3,507,548\n\n\nVesting occurs annually in three equal tranches and is not subject to performance conditions but is subject to Mr Madison remaining in office as at the date of vesting.\n\n\n\n\nGreg Madison\n\n\nRPSP\n\n\n3,507,548\n\n\nVesting occurs on 02 June 2024 and is not subject to performance conditions but is subject to Mr Madison remaining in office as at the date of vesting.\n\n\n\n \nMr Madison currently holds 1,893,039 ordinary shares in the Company.\n \n\n\n\n1.\n\n\nDetails of the Person Discharging Managerial Responsibility (\"PDMR\")/person closely associated with them (\"PCA\")\n\n\n\n\na)\n\n\nName\n\n\nGreg Madison\n\n\n\n\n2.\n\n\nReason for the notification\n\n\n\n\na)\n\n\nPosition/status\n\n\nChief Executive Officer\n \n\n\n\n\nb)\n\n\nInitial notification/\namendment\n\n\nInitial Notification\n\n\n\n\n3.\n\n\nDetails of the Issuer\n\n\n\n\na)\n\n\nName\n\n\nShield Therapeutics plc\n\n\n\n\nb)\n\n\nLEI code\n\n\n213800G74QWY15FC3W71\n\n\n\n\n4.\n\n\nDetails of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted\n\n\n\n\na)\n\n\nDescription of the financial instrument\n \nIdentification code\n\n\nOptions over new Ordinary Shares\n \n \nISIN: GB00BYV81293\n\n\n\n\nb)\n\n\nNature of the transaction\n\n\nGrant of awards over new Ordinary Shares under the Company's Reten...